The global porcine vaccines market size is expected to to reach around US$ 3,321.8 Mn by 2026 and is projected to expand at a compounded annual growth rate (CAGR) of over 8.7% from 2019 to 2026.
The report analyzes and forecasts the porcine vaccines market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of porcine vaccines, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major porcine vaccines companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of porcine vaccines upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of porcine vaccines and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global porcine vaccines market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the porcine vaccines market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of porcine vaccines market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
The report also profiles major players in the global porcine vaccines market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report are Bayer AG., Bimeda Animal Health, Boehringer Ingelheim GmbH, Ceva Santé Animale, Elanco (Eli Lilly and Company), Merck & Co., Inc., Vetoquinol, and Zoetis Inc.
The global porcine vaccines market has been segmented as below:
Global Porcine Vaccines Market, by Disease Indication, 2015–2025
Global Porcine Vaccines Market, by Technology, 2015–2025
Global Porcine Vaccines Market, by End-user, 2015–2025
Global Porcine Vaccines Market, by Geography, 2015–2025
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Chapter 1.Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2.Assumptions and Research Methodology
Chapter 3.Executive Summary : Global Porcine Vaccines Market
Chapter 4.Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Market Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Porcine Vaccines Market Analysis and Forecast, 2017–2026
4.4.1. Market Revenue Projection (US$ Mn)
4.5. Porter’s Five Forces Analysis
4.6. Market Outlook
4.7.Regulatory Scenario Assessment
4.7.1. North America
4.7.2. Europe
4.7.3. Asia Pacific
4.8.Disease Indication Comparison, by Region
4.8.1. North America
4.8.2. Europe
4.8.3. Asia Pacific
4.8.4. Latin America
4.8.5. Middle East & Africa
4.9.Swine Production Level, by Region/State
4.9.1. North America
4.9.2. Europe
4.9.3. Asia Pacific
4.9.4. Latin America
4.10.Product Launches and Innovations
4.11. Recent Market Activities
4.12.Introduction of New Types of Vaccines
4.13. Snapshot of Market Trends and Issues
Chapter 5.Global Porcine Vaccines Market Analysis and Forecast, by End-user
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Market Value Forecast by End-user, 2017–2026
5.3.1. Inactivated Vaccines
5.3.2. Live Attenuated Vaccines
5.3.3. Toxoid Vaccines
5.3.4. Recombinant Vaccines
5.3.5. Conjugate Vaccines
5.3.6. DNA Vaccines
5.4. Market Attractiveness, by End-user
Chapter 6.Global Porcine Vaccines Market Analysis and Forecast, by Disease Indication
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Disease Indication, 2017–2026
6.3.1. Diarrhea
6.3.2. Swine Influenza
6.3.3. Arthritis
6.3.4. Bordetella Rhinitis
6.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS)
6.3.6. Porcine Circovirus Associated Disease (PCVAD)
6.3.7. Others
6.4. Market Attractiveness, by Disease Indication
Chapter 7.Global Porcine Vaccines Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2017–2026
7.3.1. Veterinary Hospitals
7.3.2. Hog Production Farms
7.4. Market Attractiveness, by End-user
Chapter 8.Global Porcine Vaccines Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region
Chapter 9.North America Porcine Vaccines Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by End-user, 2017–2026
9.2.1. Inactivated Vaccines
9.2.2. Live Attenuated Vaccines
9.2.3. Toxoid Vaccines
9.2.4. Recombinant Vaccines
9.2.5. Conjugate Vaccines
9.2.6. DNA Vaccines
9.3. Market Value Forecast, by Disease Indication, 2017–2026
9.3.1. Diarrhea
9.3.2. Swine Influenza
9.3.3. Arthritis
9.3.4. Bordetella Rhinitis
9.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS)
9.3.6. Porcine Circovirus Associated Disease (PCVAD)
9.3.7. Others
9.4. Market Value Forecast, by End-user, 2017–2026
9.4.1. Veterinary Hospitals
9.4.2. Hog Production Farms
9.5. Market Value Forecast, by Country, 2017–2026
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By End-user
9.6.2. By Disease Indication
9.6.3. By End-user
9.6.4. By Country
Chapter 10.Europe Porcine Vaccines Market Analysis and Forecast
10.1.Introduction
10.1.1. Key Findings
10.2.Market Value Forecast, by End-user, 2017–2026
10.2.1. Inactivated Vaccines
10.2.2. Live Attenuated Vaccines
10.2.3. Toxoid Vaccines
10.2.4. Recombinant Vaccines
10.2.5. Conjugate Vaccines
10.2.6. DNA Vaccines
10.3.Market Value Forecast, by Disease Indication, 2017–2026
10.3.1. Diarrhea
10.3.2. Swine Influenza
10.3.3. Arthritis
10.3.4. Bordetella Rhinitis
10.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS)
10.3.6. Porcine Circovirus Associated Disease (PCVAD)
10.3.7. Others
10.4.Market Value Forecast, by End-user, 2017–2026
10.4.1. Veterinary Hospitals
10.4.2. Hog Production Farms
10.5.Market Value Forecast, by Country/Sub-region, 2017–2026
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Spain
10.5.5. Italy
10.5.6. Russia
10.5.7. Rest of Europe
10.6.Market Attractiveness Analysis
10.6.1. By End-user
10.6.2. By Disease Indication
10.6.3. By End-user
10.6.4. By Country/Sub-region
Chapter 11.Asia Pacific Porcine Vaccines Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Value Forecast, by End-user, 2017–2026
11.2.1. Inactivated Vaccines
11.2.2. Live Attenuated Vaccines
11.2.3. Toxoid Vaccines
11.2.4. Recombinant Vaccines
11.2.5. Conjugate Vaccines
11.2.6. DNA Vaccines
11.3.Market Value Forecast, by Disease Indication, 2017–2026
11.3.1. Diarrhea
11.3.2. Swine Influenza
11.3.3. Arthritis
11.3.4. Bordetella Rhinitis
11.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS)
11.3.6. Porcine Circovirus Associated Disease (PCVAD)
11.3.7. Others
11.4.Market Value Forecast, by End-user, 2017–2026
11.4.1. Veterinary Hospitals
11.4.2. Hog Production Farms
11.5.Market Value Forecast, by Country/Sub-region, 2017–2026
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6.Market Attractiveness Analysis
11.6.1. By End-user
11.6.2. By Disease Indication
11.6.3. By End-user
11.6.4. By Country/Sub-region
Chapter 12.Latin America Porcine Vaccines Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2.Market Value Forecast, by End-user, 2017–2026
12.2.1. Inactivated Vaccines
12.2.2. Live Attenuated Vaccines
12.2.3. Toxoid Vaccines
12.2.4. Recombinant Vaccines
12.2.5. Conjugate Vaccines
12.2.6. DNA Vaccines
12.3.Market Value Forecast, by Disease Indication, 2017–2026
12.3.1. Diarrhea
12.3.2. Swine Influenza
12.3.3. Arthritis
12.3.4. Bordetella Rhinitis
12.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS)
12.3.6. Porcine Circovirus Associated Disease (PCVAD)
12.3.7. Others
12.4.Market Value Forecast, by End-user, 2017–2026
12.4.1. Veterinary Hospitals
12.4.2. Hog Production Farms
12.5.Market Value Forecast, by Country/Sub-region, 2017–2026
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6.Market Attractiveness Analysis
12.6.1. By End-user
12.6.2. By Disease Indication
12.6.3. By End-user
12.6.4. By Country/Sub-region
Chapter 13.Middle East & Africa Porcine Vaccines Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2.Market Value Forecast, by End-user, 2017–2026
13.2.1. Inactivated Vaccines
13.2.2. Live Attenuated Vaccines
13.2.3. Toxoid Vaccines
13.2.4. Recombinant Vaccines
13.2.5. Conjugate Vaccines
13.2.6. DNA Vaccines
13.3.Market Value Forecast, by Disease Indication, 2017–2026
13.3.1. Diarrhea
13.3.2. Swine Influenza
13.3.3. Arthritis
13.3.4. Bordetella Rhinitis
13.3.5. Porcine Reproductive and Respiratory Syndrome (PRRS)
13.3.6. Porcine Circovirus Associated Disease (PCVAD)
13.3.7. Others
13.4.Market Value Forecast, by End-user, 2017–2026
13.4.1. Veterinary Hospitals
13.4.2. Hog Production Farms
13.5.Market Value Forecast, by Country/Sub-region, 2017–2026
13.5.1. South Africa
13.5.2. Rest of Middle East & Africa
13.6.Market Attractiveness Analysis
13.6.1. By End-user
13.6.2. By Disease Indication
13.6.3. By End-user
13.6.4. By Country/Sub-region
Chapter 14.Competition Landscape
14.1.Market Player – Competition Matrix (by Tier and Size of companies)
14.2.Market Share Analysis, by Company (2016)
14.2.1. Bayer AG
14.2.1.1. Overview
14.2.1.2. Financials
14.2.1.3. Recent Developments
14.2.1.4. Strategy
14.2.2. Bimeda Animal Health
14.2.2.1. Overview
14.2.2.2. Financials
14.2.2.3. Recent Developments
14.2.2.4. Strategy
14.2.2. Boehringer Ingelheim GmbH
14.2.3.1. Overview
14.2.3.2. Financials
14.2.3.3. Recent Developments
14.2.3.4. Strategy
14.2.4. Ceva Santé Animale
14.2.4.1. Overview
14.2.4.2. Financials
14.2.4.3. Recent Developments
14.2.4.4. Strategy
14.2.5. Elanco (Eli Lilly and Company)
14.2.5.1. Overview
14.2.5.2. Financials
14.2.5.3. Recent Developments
14.2.5.4. Strategy
14.2.6. Merck & Co., Inc.
14.2.6.1. Overview
14.2.6.2. Financials
14.2.6.3. Recent Developments
14.2.6.4. Strategy
14.2.7. Vetoquinol
14.2.7.1. Overview
14.2.7.2. Financials
14.2.7.3. Recent Developments
14.2.7.4. Strategy
14.2.8. Zoetis, Inc.
14.2.8.1. Overview
14.2.8.2. Financials
14.2.8.3. Recent Developments
14.2.8.4. Strategy
14.2.9. Others
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers